Safety endpoints
ADVERSE EVENTS, ADVERSE EVENT, EVENTS
Adverse events were reported in 50% (13 of 26) of patients for the AP30663 5 mg kgAdverse events in the safety analysis setAll data are based on investigator-reported adverse events. Data reported are the number of patients (%) and number of events (A mean decrease in heart rate was seen for all groups. This occurred earlier for the active groups compared to the placebo group, coinciding with the timing of conversions from AF to sinus rhythm (Extended Data Fig. A transient difference in change in QTcF was observed (Fig. 